However, the power of PROTACs lies in the engagement of E3 ligases, and currently, less than two percent of the vast array of E3 ligases in the human genome have been explored in the TPD field. Dr.

Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase promoting complex/cyclosome (APC/C) that is essential in mitosis and ...

One early study revealed the kinetic basis for E3 ligase domains within the Nup358/RanBP2 nucleoporin, including structural characterization of a complex between human Nup358/RanBP2, the SUMO E2 Ubc9, ...

Shanghai Yidi Biotechnology Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to an androgen receptor targeting moiety via a linker reported ...

Using this method and as a proof of principle, the researchers identified new targets of E3 ligases, RAD18 and CHIP, which are involved in cancer and neurodegenerative diseases, respectively.

Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to an androgen receptor targeting moiety through a linker acting as androgen ...

The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...

Brings extensive small molecule drug discovery, development, and clinical experience across multiple therapeutic areas Will drive application of Outrun’s novel, proprietary X-E 3 L platform for ...

DUNDEE, Scotland, Jan. 13, 2025 /PRNewswire/ -- Outrun Therapeutics ("Outrun"), the E3 ligase inhibitor and protein stabilisation specialist, today announces the appointment of Matthew Fyfe as its ...